-
In the hypoglycemic field, where many heroes compete, domestic pharmaceutical companies are competing for layout
Time of Update: 2022-03-07
It is reported that Hengrui Medicine also recently issued an announcement saying that the Class 1 chemical drug Proline Henggliflozin Tablets has been approved for marketing, becoming my country's currently approved domestic innovative SGLT2 inhibitor.
-
Under the two major trends, the pharmaceutical equipment industry will usher in new opportunities!
Time of Update: 2022-03-07
The industry expects that with the rapid development of the biopharmaceutical industry and the continuous expansion of enterprise production capacity, the disposable system will gradually replace the traditional stainless steel reactor equipment .
-
Industry: Local pharmaceutical companies go overseas, or they will be washed away by big waves!
Time of Update: 2022-03-07
Since zanubrutinib independently developed by BeiGene was approved by the US FDA in November 2019, local innovative drug companies have gradually emerged with enthusiasm for going overseas, and more and more companies have begun to embark on the road of internationalization .
-
@Pharmacist, 4 "Golden Ideas" for Seizing Market Opportunities in the Pharmaceutical Equipment Industry
Time of Update: 2022-03-07
In recent years, pharmaceutical machine giants including Chutian Technology and Tofflon have invested heavily in product research and development .
For example, pharmaceutical machine companies including Chutian and Tofflon are actively expanding their production capacity .
-
National Medical Insurance Bureau: On average, 116 drugs per province will be reduced in price, affecting all pharmacies
Time of Update: 2022-03-07
In December 2021, the person in charge of the Henan Medical Insurance Bureau clearly stated that this spring, the province will launch a pilot program of "the first batch of pharmacies to sell centralized medicines" .
-
Affected by the accelerated expansion of centralized procurement, a large number of drug prices in pharmacies have become a trend
Time of Update: 2022-03-07
Recently, at the regular policy briefing of the State Council, the relevant person in charge of the National Medical Insurance Bureau revealed that by the end of 2022, through the procurement of national organizations and provincial alliances, each province will cover more than 350 varieties of drugs and high-value medical consumables on average.
-
FDA Accepts Precision Therapeutics New Drug Application for Certain Non-Small Cell Lung Cancers
Time of Update: 2022-03-07
S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for poziotinib, a tyrosine kinase inhibitor (TKI), for the treatment of previously treated non-small cell lung cancer (NSCLC) patients with HER2 exon 20 insertion mutations .
-
The market of traditional Chinese medicine formula granules is expected to exceed 150 billion, and many pharmaceutical companies are accelerating their deployment
Time of Update: 2022-03-07
In addition, according to relevant regulations, manufacturers of traditional Chinese medicine formula granules should have complete production capacity such as processing, extraction, concentration, drying, and granulation of decoction pieces, formulate detailed production processes and standard operating procedures for each variety, and strictly implement drug production quality management.
-
17 pharmaceutical companies usher in the first innovative drug, and the new drug may achieve a blowout
Time of Update: 2022-03-07
In September 2021, WuXi Junuo's self-developed Ruiqiorenza injection was approved by the NMPA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after second-line or above systemic therapy.
-
The number of innovative traditional Chinese medicine drugs is growing "blowout", this field may benefit
Time of Update: 2022-03-07
With the rapid development of the traditional Chinese medicine industry and the continuous approval of innovative traditional Chinese medicine drugs, the traditional Chinese medicine extraction equipment industry is expected to gain opportunities .
-
4 pharmaceutical companies expect net profit to increase by over 1000% in 2021
Time of Update: 2022-03-07
8% Lisheng Pharmaceutical disclosed the performance forecast on the evening of January 21, saying that the net profit in 2021 is expected to be 110 million-140 million yuan, a year-on-year increase of 1176.
-
The national procurement of proprietary Chinese medicines is getting closer and closer, and another major news has just come out
Time of Update: 2022-03-07
For example, Qinghai, Zhejiang Jinhua, Henan Puyang and other places have carried out centralized procurement pilots for some varieties of Chinese patent medicines with large demand and high value in recent years, and achieved certain results .
-
These two pharmaceutical companies have joined forces to launch new anti-tumor drug commercialization cooperation!
Time of Update: 2022-03-07
Just recently, Baheal Pharma announced that it will "join hands" with Shanghai Yizhong, and the two sides will cooperate on the commercialization of Zisheng, an innovative tumor drug under Shanghai Yizhong, "Paclitaxel Polymeric Micellar for Injection" ("Paclitaxel Micellar" for short) .
Zisheng®, the "paclitaxel polymer micelle for injection" independently developed by Shanghai Yizhong, is a new dosage form of 2.
-
How well does AI enable small molecule drug discovery?
Time of Update: 2022-03-07
A recent article in Nature Reviews Drug Discovery analyzes the value of AI in the drug discovery process, including its impact on productivity, diversity of molecules discovered, and improvements in clinical success .
-
Pfizer's Oral Small Molecule New Coronavirus Treatment Drug Paxlovid Approved in China
Time of Update: 2022-03-07
The State Food and Drug Administration requires the marketing authorization holder to continue to carry out relevant research work, complete the conditional requirements within a time limit, and submit the follow-up research results in a timely manner .
-
The 8MW2311 immune agonist of Maiwei Bio-Injection was approved for clinical use
Time of Update: 2022-03-07
received the "Notice of Acceptance" approved and issued by the State Drug Administration, and the clinical trial application of 8MW2311 for injection was accepted .
8MW2311 for injection is a polyethylene glycol conjugated human interleukin-2 immune agonist for the treatment of advanced malignant tumors .
-
The first CD19-targeted ADC therapy launched Phase 3 clinical joint development supported by Hillhouse
Time of Update: 2022-03-07
According to public information, Lonca, developed by ADC Therapeutics, is the first FDA-approved antibody-drug conjugate targeting CD19, which can be used as a single agent for the treatment of adult patients with relapsed/refractory large B-cell lymphoma .
-
The reform of medical insurance payment is accelerated, and many provinces issue action plans
Time of Update: 2022-03-07
By the end of 2022, the province's 17 co-ordination areas will comprehensively carry out the DRG/DIP payment method reform to achieve full coverage in the co-ordination areas; by the end of 2023, all co-ordination areas will basically achieve full coverage of eligible medical institutions, diseases, and medical insurance funds; by the end of 2024, basically Establish a new medical insurance payment mechanism that is unified across the province, linked up and down, coordinated internally and externally, standardized, and efficient .
-
What's behind the NMPA's emergency approval of Pfizer's new coronavirus drug import?
Time of Update: 2022-03-07
On February 12, 2022, the State Food and Drug Administration announced that Pfizer's new coronavirus treatment drug nematevir tablet/ritonavir tablet combination package import registration has been approved with emergency conditions .
-
The research and development of PD-(L)1 is becoming more and more popular, and pharmaceutical companies need to be cautious when entering the bureau
Time of Update: 2022-03-07
_ It is worth noting that the industry believes that while more and more PD-(L)1 products are brought to the market to bring more new treatment options to the majority of patients, the competition in this track will become more intense, and product price reductions will enter the "normal" category.
